Pharma and life sciences in DACH combine pipeline, approval, and scientific depth. That shapes the sector questions. It does not automatically name the bearer of the company-wide AI yes.
Christian Pobbig and Beyond Chiefs work from Hamburg on AI Executive Search in DACH. The key distinction is between proximity to research and a named seat for AI deployment and risk.
R&D and medical teams can own AI in research or development without owning the company-wide AI yes. MedTech adjacency is real, but it does not automatically create the same responsibility.
Trial size or pipeline scale does not establish a seat. A CMO or CSO title alone likewise does not make someone the bearer of the company-wide AI decision.
No invented trial percentages or market sizes. Not a second retained-search entry under pharma. No duplicate MedTech title and no shift to a generic city description.
Search appears when a life sciences company needs the company-wide AI yes and responsibility remains open. The work then concerns seat, mandate, and judgment.
Buyers are the management board, R&D leadership, CHRO, and investors focused on life sciences. Candidates are not the audience for this distinction.
When the seat is missing, decision-makers buy the AI Executive Search mandate as retained architecture for the lasting bearer of the AI decision.
